BACKGROUND: This is a report of late effects in childhood cancer survivors seen in the follow-up clinic of a single institution. MATERIALS AND METHODS: There were 324 acute leukemia survivors in the database of the Long Term Follow Up Clinic of Children's National Medical Center from January 1, 1997, through June 30, 2005. RESULTS: Of the 324 acute leukemia survivors, 228 were white, 48 black, 20 Hispanic, and 12 other. Their follow-up time was 0 to 25 years (mean 5.3 years). One or more adverse events occurred in 74.1% of the 324 survivors. Defective physical growth was most commonly reported, followed by disturbed neurocognitive function, emotional difficulties, cardiac abnormalities, hypertension, osteoporosis/osteopenia, fractures, and second neoplasms. More black and Hispanic children had acute myeloid leukemia, relapses, cardiac problems, and hypertension than white and other subjects. CONCLUSION: Childhood cancer survivors require lifelong monitoring, with prompt identification and treatment of adverse late effects.
BACKGROUND: This is a report of late effects in childhood cancer survivors seen in the follow-up clinic of a single institution. MATERIALS AND METHODS: There were 324 acute leukemia survivors in the database of the Long Term Follow Up Clinic of Children's National Medical Center from January 1, 1997, through June 30, 2005. RESULTS: Of the 324 acute leukemia survivors, 228 were white, 48 black, 20 Hispanic, and 12 other. Their follow-up time was 0 to 25 years (mean 5.3 years). One or more adverse events occurred in 74.1% of the 324 survivors. Defective physical growth was most commonly reported, followed by disturbed neurocognitive function, emotional difficulties, cardiac abnormalities, hypertension, osteoporosis/osteopenia, fractures, and second neoplasms. More black and Hispanic children had acute myeloid leukemia, relapses, cardiac problems, and hypertension than white and other subjects. CONCLUSION: Childhood cancer survivors require lifelong monitoring, with prompt identification and treatment of adverse late effects.
Authors: K P Daly; S D Colan; E D Blume; R Margossian; K Gauvreau; C Duncan; L E Lehmann; M H Chen Journal: Bone Marrow Transplant Date: 2011-01-31 Impact factor: 5.483
Authors: Chandylen L Nightingale; Gwendolyn P Quinn; Elizabeth A Shenkman; Barbara A Curbow; Bradley J Zebrack; Kevin R Krull; I-Chan Huang Journal: J Adolesc Young Adult Oncol Date: 2011-09 Impact factor: 2.223
Authors: Etan Orgel; Nicole M Mueske; Richard Sposto; Vicente Gilsanz; Tishya A L Wren; David R Freyer; Anna M Butturini; Steven D Mittelman Journal: Leuk Lymphoma Date: 2017-02-20
Authors: Jeremy M Sharib; Jobin Cyrus; Andrew Horvai; Florette K Gray Hazard; John Neuhaus; Katherine K Matthay; Robert Goldsby; Neyssa Marina; Steven G DuBois Journal: Pediatr Blood Cancer Date: 2011-12-16 Impact factor: 3.167
Authors: Chris J Gardner; Nicola Robinson; Tim Meadows; Robert Wynn; Andrew Will; Jean Mercer; Heather J Church; Karen Tylee; J Edmond Wraith; Peter E Clayton Journal: J Inherit Metab Dis Date: 2011-01-21 Impact factor: 4.982
Authors: Christopher C Denton; Yasmin A Rawlins; Matthew J Oberley; Deepa Bhojwani; Etan Orgel Journal: Pediatr Blood Cancer Date: 2017-12-08 Impact factor: 3.167